125 / 1631
Study hypothesis
•
HDT/ASCT may be overtreating a subset of patients who have excellent outcomes
in relapsed HL
•
Radiation therapy alone can induce durable remissions, particularly in patients with
early stage disease at relapse
•
Radiation therapy induces a diverse repertoire of anti-tumor T cells, but
progression is associated with upregulation of the immune checkpoint PD-L1
•
Combination of ISRT with anti-PD1 will lead to durable remissions
A Phase II Study of Pembrolizumab and Involved Site Radiation Therapy
(ISRT) for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
PI: Craig Moskowitz, MD , Co-PI: Joachim Yahalom, MD, Santosh Vardhana MD, PhD , Gunjan Shah
MD, MS